Topics

Castle Creek Pharmaceutical Holdings to Acquire Fibrocell for $63.3 Million

09:25 EDT 13 Sep 2019 | Speciality Pharma Journal

EXTON, Pa., Sept. 12, 2019 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced it has reached an agreement to be acquired by Castle Creek Pharmaceutical Holdings, Inc. (“Castle Creek Pharmaceutical Holdings”), the parent company of …

Original Article: Castle Creek Pharmaceutical Holdings to Acquire Fibrocell for $63.3 Million

NEXT ARTICLE

More From BioPortfolio on "Castle Creek Pharmaceutical Holdings to Acquire Fibrocell for $63.3 Million"

Quick Search

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...